	US 12,473,334 B2
	SWI/SNF family chromatin remodeling complexes and uses thereof
Cigall Kadoch, Tiburon, CA (US); Nazar Mashtalir, Allston, MA (US); Brittany C. Michel, Brookline, MA (US); and Andrew D′Avino, Boston, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Appl. No. 17/283,804
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
PCT Filed Oct. 15, 2019, PCT No. PCT/US2019/056365 § 371(c)(1), (2) Date Apr. 8, 2021, PCT Pub. No. WO2020/081588, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/746,956, filed on Oct. 17, 2018.
Prior Publication US 2023/0035235 A1, Feb. 2, 2023
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); G01N 33/68 (2006.01)

CPC C07K 14/4702 (2013.01) [G01N 33/6875 (2013.01); A61K 38/00 (2013.01); C07K 2319/41 (2013.01); C07K 2319/42 (2013.01); C07K 2319/43 (2013.01); G01N 2500/04 (2013.01)]

15 Claims

1. A process for preparing an isolated modified protein complex selected from the group consisting of 1) non-canonical BAF (ncBAF) core, 2) BRD9/ncBAF core, and 3) ncBAF protein complexes, wherein the isolated modified protein complex comprises at least one GLTSCR1 or GLTSCR1L subunit that comprises a heterologous amino acid as an affinity tag or a label, comprising:

a) expressing the GLTSCR1 or GLTSCR1L subunit that comprises the heterologous amino acid as an affinity tag or a label, in a host cell or organism; and

b) isolating the modified protein complex comprising the GLTSCR1 or GLTSCR1L subunit that comprises the heterologous amino acid as an affinity tag or a label.